Table 6. Clinical features in death of rheumatoid arthritis patients with nontuberculous mycobacteria (NTM) infections.
| Variables* | n | % |
|---|---|---|
| Age at entry, (years) | ||
| mean ± SD | 73.3 ± 17.5 | |
| NTM infection in RA duration (years) | 7.0 ± 4.3 | |
| BMI†, kg/m2 | 21.3 ± 3.6 | |
| year | ||
| 18–44 | 1 | 12.5 |
| 45–64 | 1 | 12.5 |
| ≥65 | 6 | 75.0 |
| Gender | ||
| Male | 5 | 62.5 |
| TB history | 4 | 50.0 |
| Biologics used | 1† | 12.5 |
| Comorbidity | ||
| Hypertension | 5 | 62.5 |
| Cancer | 3 | 37.5 |
| COPD | 2 | 25.0 |
| CKD | 2 | 25.0 |
| Diabetes mellitus | 1 | 12.5 |
| NTM invasive site | ||
| pulmonary | 6 | 75.0 |
| extrapulmonary | 2 | 25.0 |
| Antimicrobial therapy | 5 | 62.5 |
| EMB+RIF | 2 | |
| Clarithromycin | 2 | |
| EMB+Ciprofloxacin | 1 | |
| The average time of death after NTM infection (years) | ||
| mean ± SD | 1.12 ± 0.87 | |
| NTM species | ||
| M. intracellulare | 5 | 62.5 |
| M. chelonae | 1 | 12.5 |
| M. peregrinum | 1 | 12.5 |
| M. terrae | 1 | 12.5 |
| Total | 8 | 100.0 |
*BMI, body mass index; TB, tuberculosis; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; EMB, ethambutol; RIF, rifampin.
†Actemra used, 140 days.